Lu-177 DOTATATE for hard-to-remove pheochromocytoma or paraganglioma
Treatments studied
Part of Cancer, Heart & circulation clinical trials.
This trial studies Lu-177 DOTATATE (Lutathera), a targeted radiation medicine, for tumors that cannot be safely removed with surgery. It aims to shrink or control pheochromocytoma/paraganglioma that is showing recent growth and has a specific target signal on a special PET scan.
Summary written for real people, not researchers, by Clin2.
Who can take part
- Your tumor type is pheochromocytoma (PHEO) or paraganglioma (PGL), and it can be proven by tumor testing on tissue (site review preferred, but not required).
- Surgery can’t be done (inoperable), or the main tumor can’t be fully removed, even if the cancer is only at the original spot.
- Your cancer has been growing within the last 12 months on scans (measurable disease).
- Your tumor must not have certain inherited gene causes—except SDHx—based on genetic testing you had before the study.
- Your Ga-68 DOTATATE PET scan must be positive (at least one qualifying spot that is big enough and clearly higher than background, within 12 weeks).
- You must be able to do study visits/scans and sign consent; your general health scores must be good enough (Karnofsky ≥60 or ECOG ≤2).
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This study tests whether combining Lu-177 dotatate (a targeted radiation treatment) with olaparib (a targeted pill) can shrink or slow growth of inoperable gastroenteropancreatic neuroendocrine tumors. It’s designed for tumors that show the right “targets” on a special scan and that have started to progress despite standard care.
This trial tests a new radioactive drug, [212Pb]VMT-alpha-NET, that targets a receptor found on some tumor cells. It is for people with certain gut or adrenal gland tumors that have already been treated with a similar therapy but are still growing.
This trial tests a type of radiation therapy called Lu-177 Dotatoc (PRRT) for people with neuroendocrine tumors or other cancers that have high levels of a specific protein (sst2). It may be an option when standard treatments stop working or aren't available.
This Phase 3 study tests whether a targeted radiation treatment approach (using a special “PRRT” scan-guided method) works better to control advanced neuroendocrine tumors. It’s designed for tumors that show strong targeting on a specific PET scan and that are growing despite prior treatment (with some limits).
This trial tests a new radioactive drug, Terbium-161 DOTATATE, for people with advanced neuroendocrine tumors that have stopped responding to a similar treatment called Lu-177 DOTATATE. It aims to see if this new drug is safe and can help shrink tumors.
This trial tests a personalized way to give a radioactive drug called Lutathera to people with neuroendocrine tumors (NETs). The goal is to see if adjusting the dose based on how your body absorbs it can be more effective.
Hear when a new Pheochromocytoma trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.